It’s crucial to understand that the science behind medical advancements can be extremely intricate. If you’re not deeply involved in the medical field, it might be wise to steer clear of small companies focused on research within healthcare stocks. However, this doesn’t imply you shouldn’t invest in industry titans such as Medtronic (MDT) and Merck (MRK).
Regardless of having a limited investment budget, consider these low-cost dividend providers as potential long-term holdings. Here’s the rationale behind it.
This way, the text maintains the original message but is more conversational and easier to understand for readers.
Why go with giants like Medtronic and Merck?
Small biotech startups, much like other healthcare ventures, frequently rely on groundbreaking technologies to drive their operations. If these technologies prove successful as anticipated, the stocks could potentially yield substantial returns. However, there’s always a chance that the anticipated medical advancement may not materialize as expected. In such cases, these healthcare companies might face closure, leaving shareholders with no returns.
Healthcare and science professionals might find it beneficial to consider investing in small healthcare companies that typically rely on a single breakthrough product. However, established giants such as Medtronic (in medical devices) and Merck (in pharmaceuticals) are a different category. They possess extensive collections of successful products and substantial research and development resources to create new ones.
What truly sets them apart is their strategy of acquiring smaller businesses. Companies like Medtronic and Merck, being large enough, can purchase smaller firms with cutting-edge technologies. These technologies frequently enhance their current product lines or enable them to enter new markets. In essence, they bolster their existing strength by serving as consolidators in the industry. You don’t need to stay abreast of all the science, as Medtronic and Merck are already doing that for you.
What’s to like about these buy-and-hold healthcare giants?
For dividend-focused investors, one appealing aspect of Medtronic and Merck lies in their substantial yields: 3.2% for Medtronic and 4% for Merck. In comparison, the typical healthcare stock offers a yield of approximately 1.8%, while the S&P 500 index (SNPINDEX: ^GSPC) boasts a relatively modest yield of 1.3%. This makes these companies attractive options in a market where income generation for investors is somewhat scarce in the healthcare sector.
The second point to consider is the dividend history. Medtronic has raised its dividends for an astounding 48 years in a row, nearing the requirement of 50 years to become a Dividend King. Merck’s record stands at 15 years, but it has consistently shown commitment to a growing dividend, although not every year. This may not be as remarkable as Medtronic’s streak, but it clearly shows that their board values the dividend highly.
One compelling, underlying reason for continuously investing in Medtronic and Merck is their fundamental nature. Healthcare is not a luxury; it’s essential when you’re unwell, and as you grow older, you may require even more healthcare services. This reality transforms these dependable dividend stocks into indispensable businesses. Both companies boast diverse product lines and a proven track record of adapting to advancements in healthcare technology. Given their strong positions, they are solid choices for income-focused investors today.
What will $200 get you here?
As an ardent investor, I can’t help but notice the reputation of giants like Medtronic and Merck. Their stock prices are currently on the higher side, but let me break it down: for a $200 investment, you could own two shares of either Medtronic or Merck, or even one share of each. It might not seem significant at first glance, but remember, we’re talking about established players in the healthcare sector. These companies have consistently demonstrated their value as dependable dividend stocks and long-term success stories in an industry that’s both challenging and intricate. So, while it may seem like a small step now, it could potentially be a foot in the door of a thriving, long-lasting investment opportunity.
Read More
- KPop Demon Hunters: Is Your Idol by Saja Boys Inspired by Real K-Pop Bands? Here’s What We Know
- Ultraman Live Stage Show: Kaiju Battles and LED Effects Coming to America This Fall
- Gold Rate Forecast
- Justin Bieber Teases New Album ‘SWAG’ with Tracklist Reveal
- 15 Best Sherlock Holmes Actors, Ranked from Worst to Best
- Superman’s Record-Breaking $21M+ Thursday Box Office: Highest of 2025
- Superman’s Rotten Tomatoes Score Blasts Past Expectations—Shocks Even the Harshest Critics
- 📢 BrownDust2 X BiliBili World 2025 Special Coupon!
- Tokyo Game Show 2025 exhibitors announced
- Dakota Johnson-Anne Hathaway’s Verity Release Date Out: Here’s When Colleen Hoover’s Movie Adaptation Will Hit the Screens
2025-07-19 13:15